Aktis Oncology, Inc. (AKTS)
Develops radioactive drugs that target and destroy solid tumor cancers.
$22.97-0.05%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+2.5%
The outlook
AKTS is trading near the middle of its 52-week range with strong analyst support—the consensus rates it a Strong Buy, and the average price target sits roughly 50% above the current price. The stock shows mixed momentum against its moving averages, suggesting neither clear upward nor downward technical conviction at present.
What’s behind the score
Analyst consensusStrong Buy — 1.1 avg of 6 analysts
Price trendMixed vs its moving averages
52-week range42% of the way from its 52-week low to high
Price targetAvg target +50% vs current price
Analyst price target
~12-month · 6 analysts$34.38average target+49.7% vs now
Now $22.97
Low $31.25High $40.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$1.27B
52-wk high
$34.19
52-wk low
$14.72
50-day avg
$23.61
200-day avg
$20.84
Trailing P/E
—